Vasopressin Receptor Antagonist

Vasopressin Receptor Antagonists (23):

Cat. No.	Product Name	Effect	Purity

HY-17572A

Atosiban acetate	Antagonist	99.88%
Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

HY-17572

Atosiban	Antagonist	99.55%
Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

HY-10066

Nelivaptan	Antagonist	98.35%
Nelivaptan (SSR-149415) is a selective and orally active vasopressin V1b Receptor antagonist (K_i: 3.7 and 1.3 nM for native and recombinant rat V1b receptors, respectively). Nelivaptan inhibits arginine vasopressin (AVP)-induced Ca²⁺ increase and corticotropin secretion. Nelivaptan can be used for research of stress and anxiety.

HY-19880

RWJ-676070	Antagonist
RWJ-676070 is a dual vasopressin V(1A)/V(2) receptor antagonist with an K_i value of 1.4 nM and 14 nM respectly.

HY-P1185

Antagonist G	Antagonist	99.96%
Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy.

HY-P4683A

(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin acetate	Antagonist	99.81%
(Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin is a potent vasopressin V1 receptor (VP V1R) antagonist. (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin significantly decreases the mean arterial pressure (MAP) in rats.

HY-162394

Vasopressin V2 receptor antagonist 2	Antagonist
Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V₂ receptor (V₂R) with a K_i value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].

HY-146272

Vasopressin V2 receptor antagonist 1	Antagonist
Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V₂ receptor (V₂R) antagonist with a K_i of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research.

HY-P4201

JKC 301	Antagonist
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking.

HY-139572

Enuvaptan	Antagonist
Enuvaptan (BAY-2327949) is a vasopressin receptor antagonist and has the potential for research into renal and cardiovascular diseases.

HY-P5006

(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin	Antagonist
(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin (d(CH2)5[Tyr(Me)2, Dab5]AVP) is a specific antagonist of vasopressin V_1a receptor, with a pA₂ of 6.71.

HY-P3213

Dp[Tyr(methyl)2,Arg8]-Vasopressin	Antagonist
Dp[Tyr(methyl)2,Arg8]-Vasopressin is a non-selective peptide arginine vasopressin Vlb receptor antagonist.

HY-W104304

2-(3-Trifluoromethylphenyl)glycine hydrochloride	Antagonist
2-(3-Trifluoromethylphenyl)glycine hydrochloride is a precursor of substituted 2-acetamido-5-aryl-l, 2,4-triazolones. Substituted 2-acetamido-5-aryl-l, 2,4-triazolones are dual V1a/V2 receptor antagonists and can be used in cardiovascular disease research.

HY-18344

Satavaptan	Antagonist
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia.

HY-N12638

Endolide F	Antagonist
Endolide F (Compound 2) is a proline-containing lactone. Endolide F is a moderate antagonist of the arginine antidiuretic hormone V1A receptor.

HY-157220

Tolvaptan phosphate ester sodium	Antagonist
Tolvaptan phosphate ester sodium, a prodrug of Tolvaptan (HY-17000), can be used in the study of cardiac edema. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation.

HY-P1185A

Antagonist G TFA	Antagonist
Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy.

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin	Antagonist
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist.

HY-P4994

Val9-Oxytocin	Antagonist
Val9-Oxytocin is a full antagonist of vasopressin (V_1a) receptor. Val9-Oxytocin is an analog of Oxytocin (HY-17571A) in which changing Gly9 to Val9.

HY-17572R

Atosiban (Standard)	Antagonist
Atosiban (Standard) is the analytical standard of Atosiban. This product is intended for research and analytical applications. Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

Name
Email *

	Sorry, but the email address you supplied was invalid.